---
schema_version: "secwatch.filing_event.v1"
accession: "0000882095-24-000020"
form_type: "8-K"
ticker: "GILD"
cik: "0000882095"
company_name: "GILEAD SCIENCES, INC."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:29:53.138914+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Gilead Q2 revenue $7.0B (+5%), Non-GAAP EPS $2.01; raised Non-GAAP FY guidance to $3.60-$3.90

## Summary
- Q2 2024 revenue $7.0B (+5% YoY); GAAP diluted EPS $1.29 (prior $0.83), Non-GAAP diluted EPS $2.01 (prior $1.34).
- HIV sales +3% to $4.7B; Biktarvy sales +8% to $3.2B; Oncology +15% to $841M; Trodelvy +23% to $320M.
- Full-year 2024 product sales guidance unchanged at $27.1-27.5B; non-GAAP EPS guidance raised to $3.60-$3.90; GAAP EPS lowered to $0.00-$0.30.
- Phase 3 lenacapavir for HIV prevention showed 100% efficacy in cisgender women; CymaBay acquisition closed for $3.9B.
- Product gross margin 77.7% GAAP, 86.0% non-GAAP; operating cash flow $1.3B after $1.2B transition tax payment.

## SEC filing metadata
- accession: 0000882095-24-000020
- form_type: 8-K
- ticker: GILD
- cik: 0000882095
- company_name: GILEAD SCIENCES, INC.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882095/000088209524000020/0000882095-24-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882095/000088209524000020/gild-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000882095-24-000020
- JSON: https://secwatch.observer/filing/0000882095-24-000020.json
- Plain text: https://secwatch.observer/filing/0000882095-24-000020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.